Secondary analysis of the SaveSAMS trial in 318 patients aged ≥70 with ASCVD: rosuvastatin 5 mg/ezetimibe 10 mg vs rosuvastatin 20 mg gave similar LDL target attainment, fewer muscle symptoms (0.7% vs 5.4%) and no significant difference in new-onset diabetes over 6 months.
Secondary analysisn = 318
Cha et al. Metabolic and Safety Outcomes of Statin-Ezetimibe Versus High-Intensity Statin in Older Patients